Literature DB >> 1532777

Pathogenesis of NIDDM. A balanced overview.

R A DeFronzo1, R C Bonadonna, E Ferrannini.   

Abstract

Non-insulin-dependent diabetes mellitus (NIDDM) results from an imbalance between insulin sensitivity and insulin secretion. Both longitudinal and cross-sectional studies have demonstrated that the earliest detectable abnormality in NIDDM is an impairment in the body's ability to respond to insulin. Because the pancreas is able to appropriately augment its secretion of insulin to offset the insulin resistance, glucose tolerance remains normal. With time, however, the beta-cell fails to maintain its high rate of insulin secretion and the relative insulinopenia (i.e., relative to the degree of insulin resistance) leads to the development of impaired glucose tolerance and eventually overt diabetes mellitus. The cause of pancreatic "exhaustion" remains unknown but may be related to the effect of glucose toxicity in a genetically predisposed beta-cell. Information concerning the loss of first-phase insulin secretion, altered pulsatility of insulin release, and enhanced proinsulin-insulin secretory ratio is discussed as it pertains to altered beta-cell function in NIDDM. Insulin resistance in NIDDM involves both hepatic and peripheral, muscle, tissues. In the postabsorptive state hepatic glucose output is normal or increased, despite the presence of fasting hyperinsulinemia, whereas the efficiency of tissue glucose uptake is reduced. In response to both endogenously secreted or exogenously administered insulin, hepatic glucose production fails to suppress normally and muscle glucose uptake is diminished. The accelerated rate of hepatic glucose output is due entirely to augmented gluconeogenesis. In muscle many cellular defects in insulin action have been described including impaired insulin-receptor tyrosine kinase activity, diminished glucose transport, and reduced glycogen synthase and pyruvate dehydrogenase. The abnormalities account for disturbances in the two major intracellular pathways of glucose disposal, glycogen synthesis, and glucose oxidation. In the earliest stages of NIDDM, the major defect involves the inability of insulin to promote glucose uptake and storage as glycogen. Other potential mechanisms that have been put forward to explain the insulin resistance, include increased lipid oxidation, altered skeletal muscle capillary density/fiber type/blood flow, impaired insulin transport across the vascular endothelium, increased amylin, calcitonin gene-related peptide levels, and glucose toxicity.

Entities:  

Mesh:

Year:  1992        PMID: 1532777     DOI: 10.2337/diacare.15.3.318

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  362 in total

1.  Pathogenesis of type 2 diabetes: implications for metformin.

Authors:  R A DeFronzo
Journal:  Drugs       Date:  1999       Impact factor: 9.546

Review 2.  New-onset diabetes mellitus associated with protease inhibitor therapy in an HIV-positive patient: case report and review.

Authors:  E C Lee; S Walmsley; I G Fantus
Journal:  CMAJ       Date:  1999-07-27       Impact factor: 8.262

Review 3.  Enhancing insulin action: from chemical elements to thiazolidinediones.

Authors:  R Perfetti; K Chamie
Journal:  J Endocrinol Invest       Date:  2001-04       Impact factor: 4.256

4.  Population PKPD modelling of the long-term hypoglycaemic effect of gliclazide given as a once-a-day modified release (MR) formulation.

Authors:  N Frey; C Laveille; M Paraire; M Francillard; N H G Holford; Roeline Jochemsen
Journal:  Br J Clin Pharmacol       Date:  2003-02       Impact factor: 4.335

5.  Identification of differentially expressed genes in skeletal muscle of non-diabetic insulin-resistant and insulin-sensitive Pima Indians by differential display PCR.

Authors:  Y H Lee; S Tokraks; R E Pratley; C Bogardus; P A Permana
Journal:  Diabetologia       Date:  2003-10-24       Impact factor: 10.122

6.  Impact of vitamin D supplementation during a resistance training intervention on body composition, muscle function, and glucose tolerance in overweight and obese adults.

Authors:  Andres E Carrillo; Michael G Flynn; Catherine Pinkston; Melissa M Markofski; Yan Jiang; Shawn S Donkin; Dorothy Teegarden
Journal:  Clin Nutr       Date:  2012-08-31       Impact factor: 7.324

Review 7.  Update on the treatment of type 2 diabetes mellitus.

Authors:  Juan José Marín-Peñalver; Iciar Martín-Timón; Cristina Sevillano-Collantes; Francisco Javier Del Cañizo-Gómez
Journal:  World J Diabetes       Date:  2016-09-15

8.  Protein kinase C/zeta (PRKCZ) gene is associated with type 2 diabetes in Han population of North China and analysis of its haplotypes.

Authors:  Yun-Feng Li; Hong-Xia Sun; Guo-Dong Wu; Wei-Nan Du; Jin Zuo; Yan Shen; Bo-Qin Qiang; Zhi-Jian Yao; Heng Wang; Wei Huang; Zhu Chen; Mo-Miao Xiong; Yan Meng; Fu-De Fang
Journal:  World J Gastroenterol       Date:  2003-09       Impact factor: 5.742

9.  Ragaglitazar: a novel PPAR alpha PPAR gamma agonist with potent lipid-lowering and insulin-sensitizing efficacy in animal models.

Authors:  Ranjan Chakrabarti; Reeba K Vikramadithyan; Parimal Misra; Jagadheshan Hiriyan; Suryaprakash Raichur; Ravi K Damarla; Cynthia Gershome; Juluri Suresh; Ramanujam Rajagopalan
Journal:  Br J Pharmacol       Date:  2003-09-01       Impact factor: 8.739

10.  The prolyl isomerase Pin1 increases β-cell proliferation and enhances insulin secretion.

Authors:  Yusuke Nakatsu; Keiichi Mori; Yasuka Matsunaga; Takeshi Yamamotoya; Koji Ueda; Yuki Inoue; Keiko Mitsuzaki-Miyoshi; Hideyuki Sakoda; Midori Fujishiro; Suguru Yamaguchi; Akifumi Kushiyama; Hiraku Ono; Hisamitsu Ishihara; Tomoichiro Asano
Journal:  J Biol Chem       Date:  2017-05-31       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.